Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update
Rattachement africain : it, de, au, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Cachexia, a syndrome marked by nonintentional weight loss, muscle wasting, functional decline and poor prognosis, affects 50%-80% of cancer patients, severely impacting quality of life, treatment tolerance and survival. A 'Regulatory and Trial Update Workshop' was organized by the Society on Cachexia and Wasting Disorders (SCWD) in December 2024 in Washington, DC, focused on clinical trial endpoints, standards of care and recent advancements. This article provides a summary of the discussions that were held during the first day of the workshop. Despite ongoing research, effective therapies for cachexia remain limited. Existing treatments, such as nutritional supplements, progestins, anti-inflammatories and anabolic agents, have shown mixed results, often improving appetite or lean mass without consistent functional benefits. Common muscle mass measurements, like CT scans of the L3 vertebra, are inadequate as primary endpoints because of biological variability and small effect sizes and because they do not necessarily translate into clinical benefit. Trials continue to face challenges in meeting regulatory requirements, which mandate improvements in both body composition and functional outcomes. Regulatory consensus emphasizes demonstrating clinically meaningful benefits in patient-reported outcomes/physical function and/or morbidity-mortality using validated instruments, adequate safety exposure, recognition that handgrip and weight alone are insufficient, feasibility in advanced disease, consideration of general activity measures, optional but informative body composition data and, for a pan-cancer label, benefits across at least three distinct cancers. Patient-centred endpoints, emphasizing real-life functioning and social participation, are essential as patients prioritize daily activity and independence over isolated physical measures. Clinical trials presented during the meeting included the MENAC trial, which tested a multimodal intervention combining nutrition, exercise, anti-inflammatory drugs and cancer therapy, achieved modest weight stabilization but no significant improvements in muscle mass or activity. In contrast, TCMCB07, an MC-4 receptor antagonist, demonstrated promising results in preclinical and early-phase human studies, showing weight stabilization and improved caloric intake with good tolerability. ART27.13, a dual CB1/CB2 receptor agonist, also demonstrated positive effects in appetite stimulation and weight stabilization. For S-pindolol, which targets appetite and metabolism, Phase IIb/III trials are to be initiated, following an earlier Phase II trial that showed improved muscle mass and muscle strength (hand grip strength). Future treatments must focus on integrating patient-centred goals, therapeutic mechanisms and meaningful clinical outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update
- Date Crossref
- 26/11/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Brescia Cardiology Unit pays non établi dans la noticeUniversité ou école supérieure
-
German Centre for Cardiovascular Research pays non établi dans la noticeStructure de recherche
-
University of Göttingen pays non établi dans la noticeUniversité ou école supérieure
-
The Heart Research Institute pays non établi dans la noticeStructure de recherche
-
University of Warwick pays non établi dans la noticeUniversité ou école supérieure
-
University of Mississippi pays non établi dans la noticeUniversité ou école supérieure
-
Augusta University pays non établi dans la noticeUniversité ou école supérieure
-
Edinburgh Royal Infirmary pays non établi dans la noticeÉtablissement de santé
-
University of Edinburgh Clinical Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Edinburgh Cancer Research pays non établi dans la noticeStructure de recherche
-
Charité - Universitätsmedizin Berlin pays non établi dans la noticeÉtablissement de santé
-
White Research Institute Dallas Texas USA Baylor Scott & pays non établi dans la noticeStructure de recherche
Cardiology Unit — University of Brescia, German Centre for Cardiovascular Research et University of Göttingen, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.